Beijing Healthcare developer Acctrue Raised $60M RMB Series B From Cowin Capital
A digitalization supply chain pioneer, Acctrue recently raised $60 million RMB dollars from Cowin Capital. The proceed will be used to further stabilize its leading market position, open up a bigger market, and recruit the elites so as to enhance the better capability for customers. Meanwhile, In drug electronic supervision area, Acctrue is a key supplier of national drug electronic supervision industry and has successfully provided service for more than 10,000 production lines in over 3,000 pharmaceutical companies. Its customers are large-scale and well-known foreign and domestic pharmaceutical enterprises, such as Pfizer, Johnson & Johnson, Novartis，Roche, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare Group, Sanofi-Aventis, AstraZeneca, Sinopharm, and so on.
Acctrue cover various regions such as pharmaceutical manufacturing, food processing, government regulation, iron and steel manufacturing, large-scale retail, energy and coal, aviation logistics, etc. Moreover, based on “Two Code for One Item” system, Acctrue integrates coding system and SaaS application to realize the goal of store management. Thus, the market share of Accture has reached up to 70%, and it is viewed as to №28 global company.
Cowin Capital Group, the first batch of local brand professional venture capital institution in China, has cultivated the three main investment sectors in Big technology, Big health and Big information fields. Since its establishment in 2000, Cowin has successfully invested more than 300 companies, of which 60 more became public companies, and 150 more successfully exit.
Source: https://bit.ly/2kmR24h
供應鏈數位化企業愛創科技 獲同創偉業B輪融資
供應鏈數位化企業愛創科技獲得同創偉業總額6000萬人民幣的B輪融資，資金將進一步用以鞏固公司在供應鏈數位化領域的領先地位，強化運營能力、繼續擴大市場、彙聚專業人才，提升在醫藥、快消領域的服務能力。
愛創科技致力為快消、醫藥行業客戶提供基於「一物雙碼」的整體解決方案，通過生產端的商品自動化賦碼技術切入，SaaS化應用説明客戶搭建資料中台，實現門店終端管理，愛創科技目前在醫藥行業的市占率達到70%，服務於全球Top30中的28家企業。
同創偉業是中國第一批專業創業投資公司，以「三大三新（大健康、大資訊、大消費、新能源、新材料、新工業）」為主要投資方向，成立以來旗下已設立6支PE基金，是國內處於領先地位、運作時間長和回報持續優異的本土品牌專業投資機構。
